Document |
Document Title |
WO/2013/087770A1 |
The present invention relates to quinone direct dyes of formula (I) below, organic or mineral acid or base salts thereof,tautomeric forms, optical isomers or geometrical isomers thereof and/or solvates thereof: and also to the use thereo...
|
WO/2013/090161A1 |
A process for the synthesis of a salt of tapentadol.
|
WO/2013/079578A1 |
The present invention provides a simplified method for the preparation of F-labelled compounds that is particularly suitable for automation. The method of the invention is specifically applicable where the 18F-labelled compound is prepar...
|
WO/2013/082299A1 |
Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acce...
|
WO/2013/077855A1 |
A method for the stabilization of an aqueous choline hydroxide solution includes optionally, adding a first stabilizer of a dithionite salt or a dialkylhydroxylamine to an aqueous solution containing reactants that will produce an aqueou...
|
WO/2013/076190A1 |
A method for the stabilization of an aqueous choline hydroxide solution includes, optionally adding a first stabilizer of a dithionite salt and/or a dialkylhydroxylamine to an aqueous solution containing reactants that will produce an aq...
|
WO/2013/071061A1 |
Compositions and methods for increasing resilience to the effects of stress are provided. Methods inhibit, treat, and/or prevent a stress- related disorder or symptoms thereof are provided. The method comprises increasing sphingosine-1 -...
|
WO/2013/070723A1 |
Diaminospirobisindane diols, curable compositions, curative compositions, cured articles, and methods of curing are described.
|
WO/2013/058241A1 |
The present invention makes it possible to produce (R)-2-amino-2-ethylhexanol, which is useful as a pharmaceutical intermediate, easily and efficiently without complicated procedures. (R)-2-amino-2-ethylhexanol is produced by asymmetrica...
|
WO/2013/053046A1 |
The present application, relates to iron bisphenolate complexes and methods of use and synthesis thereof. The iron complexes are prepared from tridentate or tetradentate ligands of Formula I: wherein R1 and R2 are as defined herein. Also...
|
WO/2013/052279A2 |
Amines and amine derivatives that improve the buffering range, and / or reduce the chelation and other negative interactions of the buffer and the system to be buffered. The reaction of amines or polyamines with various molecules to form...
|
WO/2013/045786A1 |
The present invention relates to the manufacture of dialkylaminoalkyl (meth)acrylate, in particular N,N-dimethylaminoethyl acrylate, by transesterification reaction of an alkyl (meth)acrylate with an amino alcohol, and the subject matter...
|
WO/2013/030803A1 |
6-chloro-3-[2-(1-ethyl-propylamino)-3,4-dioxo-cyclobut-1-eny
lamino]-2-hydroxy-N- methoxy-N-methyl-benzenesulfonamide choline, solid pharmaceutical compositions and oral dosage forms that contain said compound, and a method of using such...
|
WO/2013/028543A1 |
The disclosure relates to BAX activators and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering a therapeutically ef...
|
WO/2013/026765A1 |
The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which ...
|
WO/2013/026773A1 |
This invention relates to a novel process for the synthesis of R-biphenylalaninol and to intermediate compounds that are formed in the process according to the invention, i.e. novel intermediates useful in the synthesis of R-biphenylalan...
|
WO/2013/022919A1 |
A method for treating a p62-mediated disease (e.g., multiple myeloma) in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one p62-ZZ inhibitor compound.
|
WO/2013/018413A1 |
An alkoxide compound represented by general formula (I); and a raw material for forming a thin film, which comprises the alkoxide compound. In the formula, R1 represents a linear or branched alkyl group having 2-4 carbon atoms; and R2 an...
|
WO/2013/019655A2 |
The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder...
|
WO/2013/016263A2 |
Amine-initiated polyether polyols are made by reacting an amine adduct with a triglyceride in the presence of an alkylene oxide to obtain a polyol having a total renewables content of at least 20%. The polyols produced in this manner are...
|
WO/2011/154854A9 |
The present invention regards an improved and industrially advantageous process for the preparation of the 2-hyaroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called "feso chromenyl" and (R)-2-[3-(diisopropylamino...
|
WO/2013/016269A1 |
Provided are aminoalcohol compounds for use as additives in paints and coatings. The compounds are of the formula I:wherein p, m, n, R, R1, R2, R3, R4, R5, and R6 are as defined herein.
|
WO/2013/016270A1 |
Provided are aminoalcohol compounds for use as additives for paints and coatings. The compounds are of the formula (I): wherein x, R, R1, R2, R3, R4, R5, R6, and RA are as defined herein.
|
WO/2013/012777A2 |
A process for making a tertiary aminoalcohol compound is disclosed. The process comprises using an excess amount of a carbonyl compound in a condensation step between the carbonyl compound and a nitroalkane in the presence of a catalytic...
|
WO/2013/004190A1 |
Disclosed are immune-modulators of formula (I), the preparation method thereof, a pharmaceutical composition containing the immune-modulators, and the use of the pharmaceutical composition as a drug, especially as an immune-modulating dr...
|
WO/2013/004026A1 |
The present invention provides a process for preparing ethanolamine hydrochloride and the co-product ethanolamine. In the present process, ammonium chloride is used as a raw material for an addition reaction with EO; an appropriate formu...
|
WO/2013/000273A1 |
A method for industrially preparing a nitrogen substituted 6-amino-5,6,7,8-tetrahydronaphthol is disclosed. The method comprises reacting a nitrogen substituted amino-5,6,7,8-tetrahydronaphthol compound of formula (II) with a 2-substitut...
|
WO/2012/176927A1 |
Provided is a novel method that can produce an amino alcohol compound (2). A method for producing an amino alcohol compound represented by the formula (2): wherein R1, R2, and R3 each independently represent an alkyl group optionally hav...
|
WO/2012/171377A1 |
Disclosed is a crystal form A of asiatic acid trometamol salt, showing main peaks at diffraction angle (2θ) of 5.98, 6.87, 9.12, 10.38, 12.00, 12.47, 12.93, 13.42, 14.72, 15.10, 17.01 and 18.14 degree, and minor peaks at diffraction ang...
|
WO/2012/169909A1 |
Disclosed are salts comprising triaminocyclopropenium cations and various anions, and ionic liquids comprising the salts. Also disclosed are intermediates and methods of preparing the salts. The ionic liquids are useful as, for example, ...
|
WO/2012/150292A1 |
The invention provides for synthesis of a (S-R) dihydroxy-amino-methylalkylene characterized by the general formula I, or its R-S diastereomer, wherein R1 is CH2OH or CH2-CH2OH, and R2 is C2 to C20 alkyl, whereby a compound characterized...
|
WO/2012/145236A1 |
The present invention relates to novel substituted bicyclic methyl amine derivatives of formula (I), wherein A, Li, L2, R1 to R7 and a to c are as defined in claim 1, compositions thereof and their use in the treatment of diseases relate...
|
WO/2012/112447A9 |
The present invention provides novel compounds for inhibiting histone deacetylases, and pharmaceutically acceptable salts and derivatives thereof. The present invention further provides methods for treating disorders regulated by histone...
|
WO/2012/139212A1 |
New methods of converting pseudopterosins to pseudopteroxazoles have been developed and used to make several new non-natural pseudopteroxazole analogs. These as well as pseudopterosins and derivatives thereof and prenylated aromatic stru...
|
WO/2012/140243A1 |
The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.
|
WO/2012/136121A1 |
An amino phenylpropanoid compound, or a geometric isomer thereof, or a pharmaceutically acceptable salt or hydrate thereof as represented by Formula I, a preparation method therefor, and a pharmaceutical composition containing the compou...
|
WO/2012/126363A1 |
Disclosed are an amorphous asiatic tromethamine salt and the preparation method thereof. The method comprises the steps of: (1) dissolving asiatic acid in an organic solvent; (2) mixing with tromethamine; (3) stirring and salifying the s...
|
WO/2012/119927A1 |
The invention relates to a method for producing primary amines comprising at least one functional group of formula (-CH2-NH2), by alcohol amination of educts which comprise at least one functional group of formula (–CH2-OH), using ammo...
|
WO/2012/118441A1 |
The present invention provides an efficient and scalable process to prepare the compound of formula 4 by reduction of the corresponding α-acyloxy sulfides.
|
WO/2012/112851A2 |
A compound having a structure of formula (1), or formula (2) wherein R1 and R1a are independently hydrogen, a halo, C1-C6 straight or branched- chain alkyl, or a C1-C6 straight or branched-chain alkyl further comprising a phenyl (C6H5) g...
|
WO/2012/108777A1 |
The present invention relates to a process for the manufacture of APD and N-alkyl-APD wherein 1-CPD is reacted with aqueous ammonium or aqueous alkyl-amine under alkaline conditions and where the process is conducted in a continuous mann...
|
WO/2012/100423A1 |
Provided are compounds, and salts thereof, of formula (I): wherein (A) is R1 is hydrogen, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, C1-C5 alkanol, -(C1-C5 alkyl)phenyl, or phenyl, or a group of the formula -C(O)-R12, where R12 may be C...
|
WO/2012/100399A1 |
Provided is a process for synthesizing Fingolimod hydrochloride comprising the following steps: (1) reacting a compound (5) with a sulfhydryl compound (I) under alkaline conditions to produce a key intermediate product (6); (2) oxidizing...
|
WO/2012/098044A1 |
The invention concerns an improved process for the preparation of tolterodine (N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenyl propyl amine) and its salts, in particular for the preparation of the tartrate salt, and more particular...
|
WO/2012/089238A1 |
The invention relates to a process of making crystalline fingolimod hydrochloride of Formula (1a), comprising a step of contacting a solution of fingolimod hydrochloride in a solvent with an antisolvent at an enhanced temperature, and co...
|
WO/2012/087264A1 |
A coating composition comprising a binder, a carrier, a pigment, cations selected from the group consisting of alkali metal cations, ammonium cations, and mixtures thereof, and at least one diamino alcohol selected from the group consist...
|
WO/2012/080240A1 |
The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, parti...
|
WO/2012/080233A1 |
The invention relates to a method for purifying a reaction product containing 3-aminopropanol, said reaction product being produced in the reaction of ethylene cyanohydrin with hydrogen in the presence of ammonia, characterized in that t...
|
WO/2012/080409A1 |
A process for preparing an N,N-dialkylethanolamine of the formula (I) having high colour stability where R1 and R2 are each independently a C1- to C8-alkyl group, by reacting ethylene oxide (EO) with a corresponding dialkylamine (R1R2NH)...
|
WO/2012/074960A2 |
A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula (I) wherein R1 is independently selected from the group consisting of hydrogen, methyl, methoxy, and hydroxyl; R...
|